Related Experiment Video
Updated: May 4, 2026
05:14
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
1.7K
Switch to faricimab in various retinal diseases: real-world data
Eitan Kaplan1, Ori Segal1,2, Elad Moisseiev1,2
1Department of Ophthalmology, Meir Medical Center, Tchernichovsky 59, Kfar Saba, Israel.
International Ophthalmology
|May 2, 2026
Summary
Faricimab demonstrated efficacy in treating various retinal diseases in patients previously treated with other medications. This study shows improved outcomes and reduced fluid in eyes treated with faricimab after other therapies failed.
Area of Science:
- Ophthalmology
- Retinal diseases
- Vascular endothelial growth factor (VEGF) inhibitors
Background:
- Patients with retinal conditions often require multiple treatments.
- Previous therapies may not always achieve desired outcomes.
- Faricimab is a bispecific antibody targeting angiopoietins and VEGF.
Purpose of the Study:
- To evaluate the effectiveness of faricimab in patients with various retinal diseases who have previously undergone treatment.
- To assess anatomical and visual outcomes following faricimab therapy in a real-world setting.
Main Methods:
- Retrospective analysis of 242 eyes from 219 patients treated with faricimab.
- Patients received at least three faricimab injections between April 2023 and October 2024.
- Included diagnoses: neovascular age-related macular degeneration (NVAMD), diabetic macular edema (DME), polypoidal choroidal vasculopathy (PCV), and others.
Main Results:
- Significant reduction in intraretinal and subretinal fluid observed across all studied retinal conditions.
- Average central subfield thickness decreased, and visual acuity improved.
- Increased injection intervals and decreased pigment epithelium detachment height (in NVAMD and PCV) were noted.
Conclusions:
- Faricimab shows promise as an effective treatment option for patients with retinal diseases who have not responded adequately to prior therapies.
- The drug demonstrated positive anatomical and functional improvements in a diverse group of previously treated patients.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:27Diabetic Retinopathy
55
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
55
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:28Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
01:26FDA Approved Drugs: Changes to Approved Drugs
343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343